Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin ...

Global pharmaceutical company Sanofi is partnering with Healx, a U.K.-based clinical-stage biotech specializing in rare diseases, to use its artificial intelligence to identify novel rare disease ...

Sanofi, which is joining a growing number of ... Opella employs 11,000 people globally and sells popular French pain medicine Doliprane, as well as brands including Mucosolvan cough syrup, Allegra ...

Emanuele de Rinaldis, global head of precision medicine and computational biology at Sanofi, commented: “[O]ur drug discovery strategy is driven by precision medicine. We seek to describe ...

Sanofi, through its philanthropic organisation Foundation S, is celebrating the 25th anniversary of The Gaucher Initiative, a ...

Sanofi has unveiled a new alliance with Duke University and the Massachusetts General Hospital to mine big data to try to predict which patients will adhere to their medication – and which won't.

Brad Lightcap, COO, OpenAI "We believe AI can accelerate drug development, bringing new treatments to patients more quickly. This first product from our collaboration with Sanofi and Formation Bio is ...

This agreement follows Sanofi’s announcement of an exclusive ... This novel precision medicine approach aims at changing the standard of care in some rare cancers to extend patients’ lives ...

T1D is an autoimmune, complex, and lifelong condition – and it can happen to anyone at any age even without family history.[1 ...

Sanofi and Regeneron’s Dupixent (dupilumab ... by the regulator to treat EoE in patients aged 12 years and older, is now the ...